245 related articles for article (PubMed ID: 35062876)
1. MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis.
Du L; Wang D; Wei X; Liu C; Xiao Z; Qian W; Song Y; Hou X
BMC Gastroenterol; 2022 Jan; 22(1):29. PubMed ID: 35062876
[TBL] [Abstract][Full Text] [Related]
2. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
3. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Class-Specific Histone Deacetylase Inhibitors on the Development of Limbs During Organogenesis.
Paradis FH; Hales BF
Toxicol Sci; 2015 Nov; 148(1):220-8. PubMed ID: 26251326
[TBL] [Abstract][Full Text] [Related]
5. ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias.
D'Amato L; Dell'Aversana C; Conte M; Ciotta A; Scisciola L; Carissimo A; Nebbioso A; Altucci L
Epigenetics; 2015; 10(1):6-18. PubMed ID: 25494542
[TBL] [Abstract][Full Text] [Related]
6. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors: Isoform selectivity improves survival in a hemorrhagic shock model.
Chang P; Weykamp M; Dennahy IS; Williams AM; Bhatti UF; Liu B; Nikolian VC; Li Y; Alam HB
J Trauma Acute Care Surg; 2018 May; 84(5):795-801. PubMed ID: 29401190
[TBL] [Abstract][Full Text] [Related]
8. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
Tsapis M; Lieb M; Manzo F; Shankaranarayanan P; Herbrecht R; Lutz P; Gronemeyer H
Int J Biochem Cell Biol; 2007; 39(7-8):1500-9. PubMed ID: 17499001
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.
Steinwascher S; Nugues AL; Schoeneberger H; Fulda S
Cancer Lett; 2015 Sep; 366(1):32-43. PubMed ID: 26028172
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity.
Androutsopoulos VP; Spandidos DA
Oncol Rep; 2017 Dec; 38(6):3412-3418. PubMed ID: 29039546
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma.
Ito R; Miyanishi K; Kubo T; Hamaguchi K; Osuga T; Tanaka S; Ohnuma H; Murase K; Takada K; Nagayama M; Kimura Y; Mizuguchi T; Takemasa I; Kato J
Hepatol Int; 2023 Jun; 17(3):735-744. PubMed ID: 36738397
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
16. Detrimental effect of class-selective histone deacetylase inhibitors during tissue regeneration following hindlimb ischemia.
Spallotta F; Tardivo S; Nanni S; Rosati JD; Straino S; Mai A; Vecellio M; Valente S; Capogrossi MC; Farsetti A; Martone J; Bozzoni I; Pontecorvi A; Gaetano C; Colussi C
J Biol Chem; 2013 Aug; 288(32):22915-29. PubMed ID: 23836913
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
Zhou Q; Dalgard CL; Wynder C; Doughty ML
BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
[TBL] [Abstract][Full Text] [Related]
18. Dynamic changes in histone deacetylases following kidney ischemia-reperfusion injury are critical for promoting proximal tubule proliferation.
Hyndman KA; Kasztan M; Mendoza LD; Monteiro-Pai S
Am J Physiol Renal Physiol; 2019 May; 316(5):F875-F888. PubMed ID: 30810062
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
[TBL] [Abstract][Full Text] [Related]
20. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
